Filing Summary
Company: Daré Bioscience, Inc. Filing: Form 8-K, reporting a special stockholders’ meeting held November 10, 2026; filed November 12, 2026.
Business Context and Results
The filing reports stockholder votes, not quarterly or annual financial results. It provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no financial comparison or guidance.
| Proposal | For | Against | Abstentions | Outcome |
|---|---|---|---|---|
| Approval under Nasdaq listing rules of potential future issuance of common stock upon exercise of outstanding warrants | 5,320,515 | 2,369,554 | 38,382 | Approved |
| Adjournment, if needed, to solicit additional votes for Proposal 1 | 5,364,004 | 2,311,408 | 53,039 | Approved; adjournment was not necessary |
Key Implications and Items to Verify
- Stockholders approved the potential future issuance of shares upon exercise of outstanding warrants. This vote does not itself indicate that shares were issued or warrants exercised.
- The filing does not specify the number of shares potentially issuable, warrant terms, exercise timing, or resulting dilution; review the proxy statement filed October 6, 2026, and related disclosures for those details.
- No material financial changes, outlook, risks, or contingencies are described in this filing.